BRPI0920069A2 - biomarcadores - Google Patents

biomarcadores

Info

Publication number
BRPI0920069A2
BRPI0920069A2 BRPI0920069A BRPI0920069A BRPI0920069A2 BR PI0920069 A2 BRPI0920069 A2 BR PI0920069A2 BR PI0920069 A BRPI0920069 A BR PI0920069A BR PI0920069 A BRPI0920069 A BR PI0920069A BR PI0920069 A2 BRPI0920069 A2 BR PI0920069A2
Authority
BR
Brazil
Prior art keywords
biomarkers
Prior art date
Application number
BRPI0920069A
Other languages
English (en)
Inventor
R Wagner Daniel
Azuaje Francisco
Vausort Mélanie
Devaux Yvan
Original Assignee
Centre De Rech Public De La Santé
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre De Rech Public De La Santé filed Critical Centre De Rech Public De La Santé
Publication of BRPI0920069A2 publication Critical patent/BRPI0920069A2/pt
Publication of BRPI0920069A8 publication Critical patent/BRPI0920069A8/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
BRPI0920069A 2008-10-30 2009-10-30 Biomarcadores BRPI0920069A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10964908P 2008-10-30 2008-10-30
PCT/EP2009/064410 WO2010049538A1 (en) 2008-10-30 2009-10-30 Biomarkers

Publications (2)

Publication Number Publication Date
BRPI0920069A2 true BRPI0920069A2 (pt) 2017-06-06
BRPI0920069A8 BRPI0920069A8 (pt) 2017-10-03

Family

ID=41528764

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0920069A BRPI0920069A8 (pt) 2008-10-30 2009-10-30 Biomarcadores

Country Status (9)

Country Link
US (2) US20110294683A1 (pt)
EP (1) EP2362942B1 (pt)
JP (1) JP5749171B2 (pt)
CN (1) CN102203606A (pt)
BR (1) BRPI0920069A8 (pt)
CA (1) CA2741117A1 (pt)
ES (1) ES2640900T3 (pt)
RU (1) RU2545757C2 (pt)
WO (1) WO2010049538A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
CN106198980B (zh) 2010-08-13 2018-09-07 私募蛋白质体公司 胰腺癌生物标记及其用途
EP2592422A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients undergoing statin treatment
EP2592423A1 (en) 2011-11-08 2013-05-15 Zora Biosciences OY Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment
JP2014207883A (ja) * 2013-03-27 2014-11-06 国立大学法人岡山大学 がん幹細胞及びその用途
CN105451758A (zh) * 2013-05-31 2016-03-30 科比欧尔斯公司 用于心力衰竭的预防或治疗的人plgf-2
EP3441768A3 (en) 2013-08-26 2019-03-20 Roche Diagnostics GmbH Marker for statin treatment stratification in heart failure
CN103487586B (zh) * 2013-09-04 2015-07-15 石家庄洹众生物科技有限公司 一种定量检测可溶性生长刺激表达蛋白2的试验装置
PL228091B1 (pl) * 2014-02-12 2018-02-28 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Zestaw biomarkerów transkryptomicznych do zastosowania w stratyfikacji indywidualnego ryzyka rozwoju pozawałowej niewydolnosci serca, sposób diagnozowania ryzyka wystapienia u pacjenta pozawałowej niewydolnosci serca i zastosowanie biomarkerów do diagnostyki in vitro
WO2015183601A1 (en) * 2014-05-28 2015-12-03 Scripps Health Predictive analysis for myocardial infarction
CN105243294B (zh) * 2015-09-18 2017-06-09 淮南师范学院 一种用于预测癌症病人预后相关的蛋白质对的方法
RU2634375C2 (ru) * 2016-04-18 2017-10-26 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт кардиологии" Способ предупреждения постинфарктного ремоделирования сердца в эксперименте
WO2018009723A1 (en) * 2016-07-06 2018-01-11 Guardant Health, Inc. Methods for fragmentome profiling of cell-free nucleic acids
DE102017116204A1 (de) * 2017-07-18 2019-01-24 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration
US11708600B2 (en) * 2017-10-05 2023-07-25 Decode Health, Inc. Long non-coding RNA gene expression signatures in disease diagnosis
JP2021174119A (ja) * 2020-04-21 2021-11-01 国立大学法人横浜国立大学 画像生成装置、表示装置、画像生成方法、提示方法およびプログラム
US11915807B1 (en) * 2022-10-11 2024-02-27 Flatiron Health, Inc. Machine learning extraction of clinical variable values for subjects from clinical record data
US11854675B1 (en) 2022-10-11 2023-12-26 Flatiron Health, Inc. Machine learning extraction of clinical variable values for subjects from clinical record data

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1166102A4 (en) * 1999-03-03 2002-08-21 Ludwig Inst Cancer Res CARDIAC ANOMALIES IN ANIMALS WITHOUT ENDOTHELIAL B VASCULAR GROWTH FACTOR (VEGF-B) AND METHODS RELATING TO THESE CARDIAC ABNORMALITIES
CN1260492A (zh) * 1999-11-09 2000-07-19 赵永同 肿瘤预后评估试剂盒及其制备工艺
CN1139811C (zh) * 1999-11-09 2004-02-25 赵永同 肿瘤早期检测评估试剂盒及其制备工艺
JP4620312B2 (ja) * 1999-11-16 2011-01-26 ジェネンテック， インコーポレイテッド Ｖｅｇｆに対するエライザ
NZ522014A (en) * 2000-05-17 2007-03-30 Ludwig Inst Cancer Res Methods for detecting for the presence of tumor cells and for screening for anti-tumor agents
NZ529915A (en) * 2001-06-20 2007-07-27 Ludwig Inst Cancer Res Stimulation of vascularization of ischemic tissue by angiogenesis with VEGF-B186
CN100401063C (zh) * 2001-08-13 2008-07-09 遗传学发展股份有限公司 选择人类肿瘤最佳疗法的分子诊断和计算机决策辅助系统
US20030096248A1 (en) * 2001-09-04 2003-05-22 Vitivity, Inc. Diagnosis and treatment of vascular disease
ES2305541T3 (es) * 2002-11-16 2008-11-01 Dade Behring Marburg Gmbh Scd40l, papp-a y factor de crecimiento placentario (pigf) como combinaciones de marcadores bioquimicos en enfermedades cardiovasculares.
WO2006001888A2 (en) * 2004-04-16 2006-01-05 Acuity Pharmaceuticals Inc Compositions and methods for inhibiting angiogenesis
TW200732347A (en) * 2005-10-06 2007-09-01 Trophogen Inc VEGF analogs and methods of use

Also Published As

Publication number Publication date
BRPI0920069A8 (pt) 2017-10-03
US20160188835A1 (en) 2016-06-30
ES2640900T3 (es) 2017-11-07
EP2362942B1 (en) 2017-06-21
CN102203606A (zh) 2011-09-28
JP2012507026A (ja) 2012-03-22
RU2011121613A (ru) 2012-12-10
WO2010049538A1 (en) 2010-05-06
CA2741117A1 (en) 2010-05-06
US20110294683A1 (en) 2011-12-01
EP2362942A1 (en) 2011-09-07
JP5749171B2 (ja) 2015-07-15
RU2545757C2 (ru) 2015-04-10

Similar Documents

Publication Publication Date Title
BRPI0920069A2 (pt) biomarcadores
DK2370462T3 (da) Glucagon-analoger
BRPI0907376A2 (pt) Fotobiorretador
DK2342317T3 (da) Hængende-dråbe-plade
DE602009000234D1 (de) msignals
DK3444343T3 (da) Polypeptider
BRPI0914649A2 (pt) Piprazolo-quinazolinas
DE602008003972D1 (de) Sitzrücklehnungsmechanismus
DE602008003521D1 (de) Sitzrücklehnungsmechanismus
DK2336132T3 (da) Morpholinpurinderivat
DK2335031T3 (da) In-line-måler
DK2342454T3 (da) Vindkraftanlæg
BRPI0907637A2 (pt) Biomarcadores p53
DK2379557T3 (da) Aminopyrazol-forbindelse
DE602008003970D1 (de) Strahlstromkalibriersystem
DK2271613T3 (da) Hydroxymethylcyklohexylaminer
BRPI0907522A2 (pt) biarlamidas
DE112009001946A5 (de) Mobelauszugsführung
DE602009000488D1 (de) Obstvereinzelvorrichtung
BRPI0907863A2 (pt) pirrolopirimidinacarboxamidas
BRPI0909634A2 (pt) 2-aminoquinolinas
DE112009000183A5 (de) Sicherheitsvorreiber
BRPI0909637A2 (pt) 2-aminoquinolinas
DE602009000862D1 (de) Gehwagenbremse
AT507449A3 (de) Dämmstoffbefestiger

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: LUXEMBOURG INSTITUTE OF HEALTH (LU)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2486 DE 28-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.